Compare Alcon AG (ALC) vs ProShares Ultra Bitcoin ETF (BITU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs ProShares Ultra Bitcoin ETF — how do they compare? Alcon AG trades at $66.8 (market cap $32.69B), while ProShares Ultra Bitcoin ETF trades at $9.01. The key difference: Alcon AG pays a 0.54% dividend while ProShares Ultra Bitcoin ETF pays none, and Alcon AG is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| ALC | BITU | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.22 | $64.41 |
52-Week Low | $62.02 | $8.12 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
BITU trades at $9.48, up 7.36% in the last 24 hours, with a bullish technical signal but bearish moving averages. The stock faces structural challenges as a leveraged ETF, with key financial ratios like P/E and P/S unavailable. Recent news highlights underperformance relative to Bitcoin due to daily rebalancing decay, with Seeking Alpha rating it a Hold on June 16, 2026.
Outlook remains cautious due to BITU's leveraged structure and volatility decay risks. Investment opportunities are limited to short-term tactical plays during clear bull markets, but long-term holders face significant erosion. Primary risks include ETF mechanics, Bitcoin price dependency, and investor sentiment shifts amid crypto volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →
